JP5190062B2 - Iap阻害剤としてのピロリジン誘導体 - Google Patents

Iap阻害剤としてのピロリジン誘導体 Download PDF

Info

Publication number
JP5190062B2
JP5190062B2 JP2009532544A JP2009532544A JP5190062B2 JP 5190062 B2 JP5190062 B2 JP 5190062B2 JP 2009532544 A JP2009532544 A JP 2009532544A JP 2009532544 A JP2009532544 A JP 2009532544A JP 5190062 B2 JP5190062 B2 JP 5190062B2
Authority
JP
Japan
Prior art keywords
pyrrolidin
ethyl
cyclohexyl
pyridin
oxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2009532544A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010506847A5 (enExample
JP2010506847A (ja
Inventor
マーク・ジー・チャレスト
クリスティン・ヒウ−トゥン・チェン
チェン・ミン
チェン・チュオリアン
ダイ・ミャオ
ヘ・フェン
フアンシュ・レイ
クリストファー・ストローブ
ルン−ミン・デイビッド・ワン
リー・ザウェル
Original Assignee
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2010506847A publication Critical patent/JP2010506847A/ja
Publication of JP2010506847A5 publication Critical patent/JP2010506847A5/ja
Application granted granted Critical
Publication of JP5190062B2 publication Critical patent/JP5190062B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2009532544A 2006-10-12 2007-10-10 Iap阻害剤としてのピロリジン誘導体 Expired - Fee Related JP5190062B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US82923406P 2006-10-12 2006-10-12
US60/829,234 2006-10-12
PCT/US2007/080875 WO2008045905A1 (en) 2006-10-12 2007-10-10 Pyrrolydine derivatives as iap inhibitors

Publications (3)

Publication Number Publication Date
JP2010506847A JP2010506847A (ja) 2010-03-04
JP2010506847A5 JP2010506847A5 (enExample) 2010-12-16
JP5190062B2 true JP5190062B2 (ja) 2013-04-24

Family

ID=38984426

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009532544A Expired - Fee Related JP5190062B2 (ja) 2006-10-12 2007-10-10 Iap阻害剤としてのピロリジン誘導体

Country Status (11)

Country Link
US (1) US8044209B2 (enExample)
EP (1) EP2102229B1 (enExample)
JP (1) JP5190062B2 (enExample)
KR (1) KR20090065548A (enExample)
CN (1) CN101595121A (enExample)
AU (1) AU2007307763A1 (enExample)
BR (1) BRPI0719221A2 (enExample)
CA (1) CA2666112A1 (enExample)
MX (1) MX2009003834A (enExample)
RU (1) RU2009117701A (enExample)
WO (1) WO2008045905A1 (enExample)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007007195A (es) 2004-12-20 2007-10-08 Genentech Inc Inhibidores de pirrolidina de iap.
WO2006122408A1 (en) 2005-05-18 2006-11-23 Aegera Therapeutics Inc. Bir domain binding compounds
AU2006308453B9 (en) 2005-10-25 2011-12-01 Pharmascience Inc. IAP BIR domain binding compounds
WO2007106192A2 (en) 2005-12-19 2007-09-20 Genentech, Inc. Inhibitors of iap
TWI504597B (zh) 2006-03-16 2015-10-21 Pharmascience Inc 結合於細胞凋亡抑制蛋白(iap)之桿狀病毒iap重複序列(bir)區域之化合物
US8110681B2 (en) 2006-03-17 2012-02-07 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Compounds for the treatment of spinal muscular atrophy and other uses
BRPI0711591A2 (pt) 2006-05-16 2011-11-16 Aegera Therapeutics, Inc. composto de ligação de domìnio bir da iap
PE20110217A1 (es) * 2006-08-02 2011-04-01 Novartis Ag DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
CN101605786A (zh) * 2006-12-19 2009-12-16 健泰科生物技术公司 细胞凋亡抑制剂的咪唑并吡啶抑制剂
NZ598890A (en) * 2007-04-30 2013-10-25 Genentech Inc Inhibitors of iap
EP2296650B1 (en) 2008-05-16 2020-05-06 Novartis AG Immunomodulation by iap inhibitors
US8835393B2 (en) 2008-08-02 2014-09-16 Genentech, Inc. Inhibitors of IAP
BRPI0916576A2 (pt) 2008-08-04 2017-06-27 Chdi Inc pelo menos uma entidade química, composição farmacêutica, e, método para tratar uma condição ou distúrbio.
JP2012500272A (ja) * 2008-08-16 2012-01-05 ジェネンテック, インコーポレイテッド Iapのアザインドールインヒビター
US9643922B2 (en) 2008-08-18 2017-05-09 Yale University MIF modulators
MX2011001872A (es) * 2008-08-18 2011-05-23 Univ Yale Moduladores de mif.
US9540322B2 (en) 2008-08-18 2017-01-10 Yale University MIF modulators
US20100317593A1 (en) * 2009-06-12 2010-12-16 Astrazeneca Ab 2,3-dihydro-1h-indene compounds
UY32826A (es) 2009-08-04 2011-02-28 Takeda Pharmaceutical Compuestos heterocíclicos
MY159958A (en) 2009-12-18 2017-02-15 Idenix Pharmaceuticals Inc 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
NZ602368A (en) 2010-02-12 2014-10-31 Pharmascience Inc Iap bir domain binding compounds
US8835458B2 (en) * 2010-08-31 2014-09-16 Hanmi Science Co., Ltd Quinoline or quinazoline derivatives with apoptosis inducing activity on cells
JP2014501235A (ja) 2010-12-13 2014-01-20 ノバルティス アーゲー 二量体iap阻害剤
UY33794A (es) * 2010-12-13 2012-07-31 Novartis Ag Inhibidores diméricos de las iap
JP2014094886A (ja) * 2011-02-28 2014-05-22 Nippon Chemiphar Co Ltd Gpr119作動薬
GB201106817D0 (en) 2011-04-21 2011-06-01 Astex Therapeutics Ltd New compound
PH12014500239A1 (en) * 2011-07-28 2014-03-31 Chdi Foundation Inc Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
WO2013033068A1 (en) 2011-08-30 2013-03-07 Stephen Martin Courtney Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
SG2014012926A (en) 2011-08-30 2014-06-27 Chdi Foundation Inc Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
NO2755614T3 (enExample) 2012-01-03 2018-03-31
GB201218864D0 (en) * 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
GB201218862D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
JP6321020B2 (ja) * 2012-10-19 2018-05-09 アステックス、セラピューティックス、リミテッドAstex Therapeutics Limited 二環式複素環化合物およびそれらの治療での使用
US9980973B2 (en) 2012-10-19 2018-05-29 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
GB201218850D0 (en) * 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
CN115368356B (zh) 2013-12-20 2025-05-09 阿斯特克斯治疗有限公司 双环杂环化合物及其治疗用途
WO2015109391A1 (en) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
MX372995B (es) 2014-07-17 2020-04-13 Chdi Foundation Inc Metodos y composiciones para el tratamiento de trastornos relacionados con vih.
KR20170004160A (ko) * 2015-07-01 2017-01-11 엘지전자 주식회사 이동단말기 및 그 제어방법
TWI773657B (zh) 2015-12-18 2022-08-11 美商亞德利克斯公司 作爲非全身tgr5促效劑之經取代之4-苯基吡啶化合物
US12084472B2 (en) 2015-12-18 2024-09-10 Ardelyx, Inc. Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists
CN111247161B (zh) * 2017-11-13 2021-12-31 正大天晴药业集团股份有限公司 用作iap抑制剂的smac模拟物及其用途
WO2020027225A1 (ja) 2018-07-31 2020-02-06 ファイメクス株式会社 複素環化合物
US20220175917A1 (en) * 2019-03-07 2022-06-09 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Combination of iap inhibitor and immune checkpoint inhibitor
WO2020228642A1 (zh) * 2019-05-10 2020-11-19 正大天晴药业集团股份有限公司 一种用作iap抑制剂的smac模拟物的结晶及其制备方法
JP7764027B2 (ja) 2019-07-31 2025-11-05 ファイメクス株式会社 複素環化合物
CN112521372B (zh) * 2019-09-18 2022-07-08 南京华威医药科技集团有限公司 一种细胞凋亡蛋白抑制剂及其制备方法和用途
US20230056604A1 (en) 2020-01-20 2023-02-23 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ516918A (en) 2000-05-23 2004-06-25 Vertex Pharma Caspase inhibitors and uses thereof
WO2004007529A2 (en) * 2002-07-15 2004-01-22 The Trustees Of Princeton University Iap binding compounds
CA2491041A1 (en) 2002-07-02 2004-01-15 Novartis Ag Peptide inhibitors of smac protein binding to inhibitor of apoptosis proteins (iap)
PL2253614T3 (pl) 2004-04-07 2013-03-29 Novartis Ag Inhibitory IAP
KR100926203B1 (ko) * 2004-07-02 2009-11-09 제넨테크, 인크. Iap의 억제제
MX2007007195A (es) * 2004-12-20 2007-10-08 Genentech Inc Inhibidores de pirrolidina de iap.
WO2007106192A2 (en) * 2005-12-19 2007-09-20 Genentech, Inc. Inhibitors of iap

Also Published As

Publication number Publication date
KR20090065548A (ko) 2009-06-22
US20110015232A1 (en) 2011-01-20
EP2102229A1 (en) 2009-09-23
RU2009117701A (ru) 2010-11-20
US8044209B2 (en) 2011-10-25
CN101595121A (zh) 2009-12-02
BRPI0719221A2 (pt) 2014-03-18
CA2666112A1 (en) 2008-04-17
JP2010506847A (ja) 2010-03-04
AU2007307763A1 (en) 2008-04-17
WO2008045905A1 (en) 2008-04-17
MX2009003834A (es) 2009-04-22
EP2102229B1 (en) 2014-03-26

Similar Documents

Publication Publication Date Title
JP2010506847A (ja) Iap阻害剤としてのピロリジン誘導体
EP2537846B1 (en) Intermediate compounds for preparing SMAC peptidomimetics
EP2086938B1 (en) Organic compounds
JP2008545780A (ja) 有機化合物
KR20080083220A (ko) Iap 억제제
JP2010512321A (ja) 増殖疾患の処置における6−オキソ−1,6−ジヒドロピリミジン−2−イル化合物
HK1176613B (en) Intermediate compounds for preparing smac peptidomimetics
HK1127616B (en) Smac peptidomimetics useful as iap inhibitors
HK1176612A (en) Organic compounds
HK40050670A (en) Substituted piperidines as cxcr4-inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101005

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20101005

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121113

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121130

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130108

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130125

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20160201

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees